Forian Inc. FORA
We take great care to ensure that the data presented and summarized in this overview for Forian Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FORA
View all-
Oracle Investment Management Inc Greenwich, CT1.37MShares$2.68 Million7.7% of portfolio
-
Staley Capital Advisers Inc1.1MShares$2.16 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA775KShares$1.52 Million0.0% of portfolio
-
Elser Financial Planning, Inc Indianapolis, IN559KShares$1.09 Million0.07% of portfolio
-
Canton Hathaway, LLC270KShares$528,5140.14% of portfolio
-
Geode Capital Management, LLC Boston, MA170KShares$333,1700.0% of portfolio
-
Caprock Group, Inc.86.8KShares$170,0960.01% of portfolio
-
Grey Street Capital, LLC Chicago, IL86.8KShares$170,0960.04% of portfolio
-
Black Rock Inc. New York, NY84.7KShares$166,0000.0% of portfolio
-
State Street Corp Boston, MA53.9KShares$105,5610.0% of portfolio
Latest Institutional Activity in FORA
Top Purchases
Top Sells
About FORA
Forian Inc. provides software solutions, proprietary data driven insights, and predictive analytics to optimize the operational, clinical, and financial performance of its healthcare, cannabis, and government customers. It operates through three segments: Information & Software, Services, and Other. The company's products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides clients with a presentation of business performance. Its products also comprise BioTrack seed-to-sale compliance traceability platform, which is used to manage the tracking and tracing of various cannabis products from cultivation to sale; BioTrack State Traceability & Enforcement Monitoring System to ensure transparency and accountability throughout cannabis supply chain; and STEMS, a seed-to-sale tracking module, to provide cannabis program management solution to cannabis regulatory agencies. In addition, the company offers security monitoring and web marketing services. The company is headquartered in Newtown, Pennsylvania.
Insider Transactions at FORA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 05
2025
|
Edward Francis Spaniel Jr EVP, Gen Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
7,769
-0.79%
|
$15,538
$2.06 P/Share
|
|
Feb 14
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Open market or private purchase
|
Direct |
880
+0.07%
|
$1,760
$2.96 P/Share
|
|
Feb 13
2025
|
Michael Vesey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,971
-1.13%
|
$9,942
$2.76 P/Share
|
|
Feb 13
2025
|
Edward Francis Spaniel Jr EVP, Gen Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,426
-0.55%
|
$10,852
$2.76 P/Share
|
|
Feb 13
2025
|
Adam H Dublin Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,494
-0.61%
|
$30,988
$2.76 P/Share
|
|
Feb 13
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Open market or private purchase
|
Direct |
1,800
+0.14%
|
$3,600
$2.73 P/Share
|
|
Feb 12
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Open market or private purchase
|
Direct |
1,747
+0.13%
|
$3,494
$2.52 P/Share
|
|
Feb 11
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Open market or private purchase
|
Direct |
12,320
+0.46%
|
$24,640
$2.77 P/Share
|
|
Feb 10
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+0.14%
|
$3,600
$2.45 P/Share
|
|
Feb 07
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+0.15%
|
$4,000
$2.49 P/Share
|
|
Feb 06
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+0.14%
|
$3,600
$2.48 P/Share
|
|
Feb 05
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
1,700
+0.13%
|
$3,400
$2.42 P/Share
|
|
Feb 04
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
1,700
+0.13%
|
$3,400
$2.35 P/Share
|
|
Feb 03
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+0.2%
|
$5,200
$2.24 P/Share
|
|
Jan 31
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+0.2%
|
$5,200
$2.24 P/Share
|
|
Jan 30
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
1,708
+0.13%
|
$3,416
$2.26 P/Share
|
|
Jan 29
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
1,700
+0.13%
|
$3,400
$2.32 P/Share
|
|
Jan 24
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+0.61%
|
$16,000
$2.24 P/Share
|
|
Jan 23
2025
|
Max C Wygod Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
3,822
+0.3%
|
$7,644
$2.1 P/Share
|
|
Jan 12
2025
|
Michael Vesey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,089
-3.96%
|
$36,178
$2.05 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 429K shares |
|---|---|
| Open market or private purchase | 16.7K shares |
| Payment of exercise price or tax liability | 71.1K shares |
|---|